Avidity Biosciences (RNA) Short Interest Ratio & Short Volume $43.65 +0.40 (+0.92%) (As of 11/20/2024 ET) Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrends Avidity Biosciences Short Interest DataAvidity Biosciences (RNA) has a short interest of 14.66 million shares. This marks a -1.48% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.5, indicating that it would take 11.5 days of the average trading volume of 1.11 million shares to cover all short positions.Current Short Interest14,660,000 sharesPrevious Short Interest14,880,000 sharesChange Vs. Previous Month-1.48%Dollar Volume Sold Short$619.53 millionShort Interest Ratio11.5 Days to CoverLast Record DateOctober 31, 2024Outstanding Shares119,310,000 sharesPercentage of Shares Shorted12.29%Today's Trading Volume675,384 sharesAverage Trading Volume1,107,051 sharesToday's Volume Vs. Average61% Short Selling Avidity Biosciences? Sign up to receive the latest short interest report for Avidity Biosciences and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartRNA Short Interest Over TimeRNA Days to Cover Over TimeRNA Percentage of Float Shorted Over Time Ad Darwin2025 AI Stock Picks: 2 Hidden Gems Under $10/ShareThe AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months.👉[Click here to get your FREE report delivered instantly!] Avidity Biosciences Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 10/31/202414,660,000 shares $619.53 million -1.5%N/A11.5 $42.26 10/15/202414,880,000 shares $694.90 million +0.7%N/A11.2 $46.70 9/30/202414,770,000 shares $678.39 million +23.3%N/A10.3 $45.93 9/15/202411,980,000 shares $499.69 million +10.8%N/A7.9 $41.71 8/31/202410,810,000 shares $475.64 million -16.3%N/A6.6 $44.00 8/15/202412,920,000 shares $587.73 million -0.2%N/A7.8 $45.49 Get the Latest News and Ratings for RNA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Avidity Biosciences and its competitors with MarketBeat's FREE daily newsletter. 7/31/202412,950,000 shares $590.26 million +0.3%N/A8.2 $45.58 7/15/202412,910,000 shares $588.95 million +19.2%N/A8.5 $45.62 6/30/202410,830,000 shares $442.41 million -3.9%N/A7.6 $40.85 6/15/202411,270,000 shares $446.74 million +4.2%N/A8.4 $39.64 5/31/202410,820,000 shares $290.63 million -4.3%N/A10 $26.86 5/15/202411,310,000 shares $333.76 million -0.7%N/A9.3 $29.51 4/30/202411,390,000 shares $274.84 million +6.9%N/A10 $24.13 4/15/202410,660,000 shares $254.88 million +6.8%N/A9 $23.91 3/31/20249,980,000 shares $254.69 million +15.8%N/A8.2 $25.52 3/15/20248,620,000 shares $210.50 million +10.9%N/A7.3 $24.42 2/29/20247,770,000 shares $142.19 million +0.5%N/A6.5 $18.30 2/15/20247,730,000 shares $104.59 million +1.2%N/A5.4 $13.53 1/31/20247,640,000 shares $93.44 million +4.1%N/A5.4 $12.23 1/15/20247,340,000 shares $83.31 million -25.3%N/A5.5 $11.35 12/31/20239,830,000 shares $88.96 million -8.0%N/A7.4 $9.05 12/15/202310,680,000 shares $92.38 million -3.2%N/A8.5 $8.65 11/30/202311,030,000 shares $86.14 million +1.5%N/A9 $7.81 11/15/202310,870,000 shares $67.72 million -6.3%N/A13.7 $6.23 10/31/202311,600,000 shares $59.74 million +0.3%N/A14.7 $5.15 10/15/202311,570,000 shares $71.50 million -25.3%N/A14.5 $6.18 9/30/202315,490,000 shares $98.83 million -7.4%N/A20.3 $6.38 9/15/202316,720,000 shares $117.21 million +2.1%N/A21.3 $7.01 8/31/202316,380,000 shares $123.83 million +2.0%N/A18.2 $7.56 8/15/202316,060,000 shares $139.40 million +2.8%N/A17.9 $8.68 7/31/202315,620,000 shares $148.55 million -2.7%N/A15.7 $9.51 7/15/202316,050,000 shares $173.82 million +2.2%N/A13.4 $10.83 6/30/202315,710,000 shares $174.22 million +11.4%N/A12 $11.09 6/15/202314,100,000 shares $175.97 million +5.2%N/A9.7 $12.48 5/31/202313,400,000 shares $142.31 million +4.4%N/A10.1 $10.62 5/15/202312,840,000 shares $144.45 million +29.3%N/A9.5 $11.25 4/30/20239,930,000 shares $123.13 million -12.4%N/A7.6 $12.40 4/15/202311,330,000 shares $169.72 million +3.9%N/A10.6 $14.98 3/31/202310,910,000 shares $167.47 million +25.6%N/A10.5 $15.35 3/15/20238,690,000 shares $184.05 million +4.6%N/A9.1 $21.18New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 2/28/20238,310,000 shares $196.95 million +5.5%N/A4.2 $23.70 2/15/20237,880,000 shares $194.64 million +5.1%N/A4.1 $24.70 1/31/20237,500,000 shares $177.75 million -4.7%N/A3.9 $23.70 1/15/20237,870,000 shares $178.26 million -5.0%N/A4.1 $22.65 12/30/20228,280,000 shares $183.73 million +27.2%N/A4.5 $22.19 12/15/20226,510,000 shares $118.16 million -7.3%N/A3.6 $18.15 11/30/20227,020,000 shares $81.71 million -0.1%N/A11.6 $11.64 11/15/20227,030,000 shares $100.53 million +26.7%N/A13.2 $14.30 10/31/20225,550,000 shares $79.25 million +12.6%N/A11.8 $14.28 10/15/20224,930,000 shares $80.90 million +7.4%N/A11.1 $16.41 9/30/20224,590,000 shares $74.95 million -13.4%N/A11.8 $16.33 9/15/20225,300,000 shares $112.36 million +0.8%N/A16.3 $21.20 8/31/20225,260,000 shares $103.20 million -5.6%N/A15.1 $19.62 8/15/20225,570,000 shares $123.71 million -4.5%N/A15.5 $22.21 7/31/20225,830,000 shares $94.97 million -1.2%N/A15.8 $16.29 7/15/20225,900,000 shares $103.43 million +4.1%N/A16.6 $17.53 6/30/20225,670,000 shares $82.39 million +15.0%N/A16.4 $14.53 6/15/20224,930,000 shares $59.31 million +4.9%N/A15.2 $12.03 5/31/20224,700,000 shares $65.47 million +9.3%N/A19.1 $13.93 5/15/20224,300,000 shares $55.69 million +4.6%N/A17.4 $12.95 4/30/20224,110,000 shares $58.77 million +2.8%N/A16.7 $14.30 4/15/20224,000,000 shares $72.88 million -0.3%N/A15.9 $18.22 3/31/20224,010,000 shares $74.06 million +1.3%N/A14.9 $18.47 3/15/20223,960,000 shares $63.44 million +2.3%N/A14.8 $16.02 2/28/20223,870,000 shares $65.64 million +1.8%N/A14 $16.96 2/15/20223,800,000 shares $63.65 million +5.0%N/A13.2 $16.75 1/31/20223,620,000 shares $60.16 million -4.0%N/A14.4 $16.62 1/15/20223,770,000 shares $67.22 million -4.6%N/A16 $17.83 12/31/20213,950,000 shares $93.89 million -7.3%N/A17.9 $23.77 12/15/20214,260,000 shares $103.60 million -9.4%N/A19.1 $24.32 11/30/20214,700,000 shares $104.95 million -3.3%N/A17.6 $22.33 11/15/20214,860,000 shares $119.99 million -8.7%N/A14.9 $24.69 10/29/20215,320,000 shares $119.70 million +1.3%N/A16.4 $22.50 10/15/20215,250,000 shares $112.98 million -6.9%N/A14.4 $21.52 9/30/20215,640,000 shares $138.91 million +3.9%N/A15.3 $24.63 9/15/20215,430,000 shares $124.24 million -16.7%N/A13.7 $22.88 8/31/20216,520,000 shares $148.92 million +3.7%N/A18.4 $22.84 8/13/20216,290,000 shares $122.72 million +3.6%N/A24.1 $19.51 7/30/20216,070,000 shares $117.21 million +0.2%N/A23.5 $19.31 7/15/20216,060,000 shares $135.74 million -1.1%19.0%27.8 $22.40 6/30/20216,130,000 shares $151.47 million -4.2%19.2%26.8 $24.71 6/15/20216,400,000 shares $168.38 million -2.4%20.1%28.3 $26.31 5/28/20216,560,000 shares $155.73 million -0.5%20.6%22.9 $23.74 5/14/20216,590,000 shares $129.30 million +1.2%20.7%20.3 $19.62 4/30/20216,510,000 shares $158.84 million +2.2%20.5%17.3 $24.40 4/15/20216,370,000 shares $135.62 million +9.6%20.1%16.4 $21.29 3/31/20215,810,000 shares $117.83 million +30.6%18.3%15.3 $20.28 3/15/20214,450,000 shares $114.10 million +21.9%14.0%11.7 $25.64 2/26/20213,650,000 shares $92.75 million +14.4%11.5%11.8 $25.41 2/12/20213,190,000 shares $70.91 million +8.5%10.1%11.8 $22.23New Year, New Opportunity! 2 AI Stocks Under $10 Ready to Soar (Ad)As we step into 2025, artificial intelligence (AI) stocks continue to dominate headlines, and now is the perfect moment to position yourself for the coming year’s potential. Our latest research has uncovered two must-buy AI stocks currently trading under $10/share – an affordable entry with promising growth potential. These stocks are flying under the radar, but it’s only a matter of time before they gain mainstream attention.👉 Click here to access your FREE report now! 1/29/20212,940,000 shares $67.56 million -7.3%9.3%14.3 $22.98 1/15/20213,170,000 shares $84.58 million No Change10.0%16.1 $26.68 RNA Short Interest - Frequently Asked Questions What is Avidity Biosciences' current short interest? Short interest is the volume of Avidity Biosciences shares that have been sold short but have not yet been closed out or covered. As of October 31st, investors have sold 14,660,000 shares of RNA short. Learn More on Avidity Biosciences' current short interest. What is a good short interest ratio for Avidity Biosciences? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. RNA shares currently have a short interest ratio of 12.0. Learn More on Avidity Biosciences's short interest ratio. Which institutional investors are shorting Avidity Biosciences? As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Avidity Biosciences: Jane Street Group LLC, and Citigroup Inc.. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission. Is Avidity Biosciences' short interest increasing or decreasing? Avidity Biosciences saw a decrease in short interest in the month of October. As of October 31st, there was short interest totaling 14,660,000 shares, a decrease of 1.5% from the previous total of 14,880,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Avidity Biosciences' short interest compare to its competitors? Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Avidity Biosciences: ORIC Pharmaceuticals, Inc. (16.51%), Solid Biosciences Inc. (4.40%), Nkarta, Inc. (13.56%), Teva Pharmaceutical Industries Limited (1.60%), BeiGene, Ltd. (1.12%), Viatris Inc. (2.09%), Summit Therapeutics Inc. (2.31%), Moderna, Inc. (10.02%), Genmab A/S (0.37%), Dr. Reddy's Laboratories Limited (1.28%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: Charter Communications, Inc. ($4.08 billion), AppLovin Co. ($3.18 billion), Paychex, Inc. ($2.64 billion), Nu Holdings Ltd. ($2.54 billion), International Paper ($2.46 billion), Cencora, Inc. ($2.27 billion), Moderna, Inc. ($1.87 billion), SoFi Technologies, Inc. ($1.81 billion), Lululemon Athletica Inc. ($1.75 billion), and Onsemi ($1.71 billion). View all of the most shorted stocks. What does it mean to sell short Avidity Biosciences stock? Short selling RNA is an investing strategy that aims to generate trading profit from Avidity Biosciences as its price is falling. RNA shares are trading up $0.40 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Avidity Biosciences? A short squeeze for Avidity Biosciences occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of RNA, which in turn drives the price of the stock up even further. How often is Avidity Biosciences' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including RNA, twice per month. The most recent reporting period available is October, 31 2024. More Short Interest Resources from MarketBeat Related Companies ORIC Pharmaceuticals Short Squeeze Solid Biosciences Short Squeeze Nkarta Short Squeeze Teva Pharmaceutical Industries Short Squeeze BeiGene Short Squeeze Viatris Short Squeeze Summit Therapeutics Short Squeeze Moderna Short Squeeze Genmab A/S Short Squeeze Dr. Reddy's Laboratories Short Squeeze Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:RNA) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | SponsoredJD Vance Predicts: Wall Street vs. Trump & Your MoneyTrump's back in the White House, but Wall Street is pissed. Here's the deal: Wall Street's about to purpose...Priority Gold | SponsoredTrump won. Buy this coin now.Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will ...Weiss Ratings | SponsoredTrump said you could learn something from this manEarly Warning: A Deep Crack Is Forming In The US Economy Stocks are booming thanks to Trump’s landslide vic...Wide Moat Research | SponsoredThis Bull Market Indicator called NVDA at $116Every now and again we find an investment idea so incredible we can’t help but share. And today is one of ...WealthPress | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Avidity Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Avidity Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.